4 Buy-Rated S&P 500 Stocks to Scoop Up on the Dip

The S&P 500 index has suffered extreme volatility amid the resurgence of COVID-19 cases and the emergence of the omicron  variant. On December 1, the United States identified its first known COVID-19 case caused by…

the omicron variant. This has raised investor fears about the economic recovery. But according to JPMorgan analysts, the rise in the S&P 500 will not be hampered because of the omicron variant despite the recent stock market pullback.

In addition, a positive analysis by a team of strategists at Goldman Sachs claims that “Omicron is slightly more transmissible but causes much less severe disease,” as reported from the initial case findings in South Africa. Furthermore,  most experts seem to be convinced by this analysis for now.

Therefore, we think it could be wise to bet on fundamentally sound S&P 500 stocks Vertex Pharmaceuticals Incorporated (VRTXGet Rating), Agilent Technologies, Inc. (AGet Rating), HP Inc. (HPQGet Rating), and McKesson Corporation (MCKGet Rating). These stocks are currently trading below their 52-week highs but have Strong Buy or Buy rating in our proprietary POWR Ratings system.

Vertex Pharmaceuticals Incorporated (VRTXGet Rating)

Boston-based biotechnology company VRTX develops and commercializes therapies to treat cystic fibrosis. It also pursues scientific innovation to create transformative medicines for people with serious diseases.

On November 19, 2021, VRTX announced that the Spanish government had approved its terms for the national reimbursement of KAFTRIO in a combination regimen with ivacaftor for treating cystic fibrosis for eligible patients. Ludovic Fenaux, Senior Vice President, Vertex International, said, “The formalized agreement is an important milestone for people living with cystic fibrosis in Spain. We are pleased that the Ministry of Health recognized the value of KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor.”

VRTX’s net product revenues increased 29.2% year-over-year to $1.98 billion for its  fiscal third quarter, ended September 30, 2021. Its non-GAAP operating income came in at $1.19 billion, up 39.1% year-over-year. While its non-GAAP net income increased 32.9% year-over-year to $926 million, its non-GAAP EPS came in at $3.56, up 34.8% year-over-year.

Analysts expect VRTX’s revenue to be $7.50 billion in its fiscal year 2021, representing a 20.9% year-over-year rise. The company’s EPS is expected to increase 23.4% year-over-year to $12.74 in the current year. It surpassed the Street’s EPS estimates in three of the trailing four quarters. Over the past month, the stock has gained 10.6% in price to close yesterday’s trading session at $205. It is currently trading 15.6% below its 52-week high of $242.99, which it hit on January 25, 2021.

VRTX’s strong fundamentals are reflected in its POWR Ratings. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting. The stock has an overall A rating, which indicates a Strong Buy in our proprietary rating system.

VRTX has an A grade for Value and Quality and a B grade for Growth and Sentiment. It is ranked #3 of 476 stocks in the Biotech industry. Click here to see the additional POWR Ratings for Momentum and Stability for VRTX.

Click here to checkout our Healthcare Sector Report for 2021

Agilent Technologies, Inc. (AGet Rating)

A provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Santa Clara, Calif.-based company functions primarily through Life Sciences and Applied Markets, and the Diagnostics, Genomics, and the Agilent CrossLab segments.

On November 1, 2021, A announced new Agilent 6560C Ion Mobility LC/Q-TOF, enhancements to the VWorks automation software suite, and new AssayMAP large capacity cartridges. Sudharshana Seshadri, vice president and general manager of A’s Mass Spectrometry Division, said, “These introductions reinforce Agilent’s commitment to supporting and enhancing the speed of discovery and development of novel protein biotherapeutics to improve the quality of life.”

A’s net revenue increased 11.9% year-over-year to $1.66 billion in its  fiscal fourth quarter, ended October 31, 2021. Its income from operations came in at $395 million, up 32.1% year-over-year. While its non-GAAP net income increased 20.7% year-over-year to $368 million, its non-GAAP EPS came in at $1.21, up 23.5% year-over-year.

Analysts expect A’s revenue and EPS to increase 7.1% and 11.5%, respectively, year-over-year to $5.99 billion and $4.28 in its fiscal year 2022. Over the past nine months, the stock has gained 19.1% in price to close yesterday’s trading session at $148.21. It is currently trading 17.5% below its 52-week high of $179.57, which it hit on September 3, 2021.

A’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall A rating, which indicates a Strong Buy in our proprietary rating system.

A has a B grade for Value, Stability, Sentiment, and Quality. Within the Medical-Diagnostics/Research industry, it is ranked #2 out of 55 stocks. Click here to see the additional POWR Rating for Growth and Momentum for A.

Note that A is one of the few stocks handpicked by our Chief Growth Strategist, Jaimini Desai, currently in the POWR Growth portfolio. Learn more here.

HP Inc. (HPQGet Rating)

HPQ provides personal computing and other access devices, imaging and printing products, and related technologies, solutions, and services in the USA and internationally. The Palo Alto, Calif., company operates through three segments: Personal Systems; Printing; and Corporate Investments.

On November 23, 2021, Enrique Lores, HPQ President and CEO, said…

 

Continue reading at STOCKNEWS.com

 

You May Also Like

About the Author: admin

Leave a Reply

Your email address will not be published. Required fields are marked *